Patrick Schöffski

39PUBLICATIONS
244CO-AUTHORS
Biologically active moleculesGene and molecular therapyEvolutionary ecologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Aug 14, 2026
Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts.

|Jul 01, 2026
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

|Jun 11, 2026
Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Mar 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Mrinal Gounder, Patrick Schöffski, Robin L Jones

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

Pageof 7

Frequent Collaborators

10 joint publications

Raf Sciot

9 joint publications

Agnieszka Wozniak

7 joint publications

Jean-Yves Blay

6 joint publications

Robin L Jones